An official website of the United States government
Publication Information
Affiliation
UNC Liver Center, Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, NC 27599, USA. mfried@med.unc.edu
Authors
Afdhal N, Batey B, Belle S, Belle SH, Blumenthal M, Bodenheimer HC, Borg E, Bowen J, Colagreco J, Davis P, Doo E, Dougherty KA, Duffy L, Elliott S, Evon D, Fried MW, Gupta D, Hawke R, Hawke RL, Hoofnagle J, Howell M, Kaplan DE, Kennedy C, Kurs-Lasky M, Laurin J, Lawlor S, McFann KK, Meyers C, Meyers CM, Miller C, Navarro V, Navarro VJ, Reddy K, Reddy KR, Schrieber S, Seeff L, Shader RI, Silymarin in NASH and C Hepatitis (SyNCH) Study Group, Soule T, Verma M, Wahed A, Wahed AS, Walton A, Wirjosemito A, Zadorozny E
Studies
Citation
Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, Doo E, Meyers CM, Reddy KR, Silymarin in NASH and C Hepatitis (SyNCH) Study Group. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA 2012 Jul 18;308(3):274-82.Abstract
The botanical product silymarin, an extract of milk thistle, is commonly used by patients to treat chronic liver disease, despite scant and conflicting evidence of its efficacy.